Gerard Roy, MD
Obstetrics & Gynecology · New Britain, CTNPI 1992775910
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Exeltis, USA Inc.$522
- Sumitomo Pharma America, Inc.$422
- Astellas Pharma US Inc$385
- Pfizer$371
- Coopersurgical, Inc.$335
- plus $3K from 25 others
What the payments were for
- Food & beverage$5,68998%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,205 |
| Exeltis, USA Inc. | 25 | $522 |
| Sumitomo Pharma America, Inc. | 18 | $422 |
| Astellas Pharma US Inc | 20 | $385 |
| Pfizer | 18 | $371 |
| Coopersurgical, Inc. | 16 | $335 |
| Agile Therapeutics, Inc. | 14 | $285 |
| Merck | 14 | $274 |
| Lupin Inc. | 14 | $200 |
| Millicent US Inc | 11 | $198 |
| Therapeuticsmd, Inc. | 11 | $197 |
| Bayer | 11 | $184 |
| Exact Sciences | 7 | $154 |
| Mylan Pharmaceuticals Inc. | 9 | $142 |
| Sage Therapeutics, LLC | 6 | $124 |
| Mayne Pharma Commercial LLC | 6 | $108 |
| Urovant Sciences Inc | 5 | $106 |
| Duchesnay USA Incorporated | 4 | $98 |
| Organon | 5 | $93 |
| AMAG Pharmaceuticals, Inc. | 5 | $92 |
| Aspira Women's Health Inc | 3 | $77 |
| Daiichi Sankyo Inc. | 3 | $49 |
| GE HealthCare | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $21 |
| Shield Therapeutics Inc | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Conmed Corporation | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Monaghan Medical Corporation | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
| Innovation Technologies Inc | 1 | $14 |
How this compares
$5,781 in reported general payments places this provider in the 90th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 23 | $32,505 |
| OzempicSemaglutide | 19 | $18,110 |
| MyrbetriqMirabegron | 12 | $10,765 |
| YuvafemEstradiol | 18 | $2,562 |
| Risedronate Sodium | 46 | $2,394 |
| Estradiol | 44 | $1,567 |
| Desipramine Hcl | 13 | $999 |
| ClimaraEstradiol | 12 | $859 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $593 |
| Terconazole | 19 | $588 |
| Fluconazole | 53 | $517 |
| Metronidazole | 20 | $483 |
| ValacyclovirValacyclovir Hcl | 18 | $439 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $424 |
| Triamcinolone Acetonide | 36 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $422 | $32,50523 claims |
| Astellas Pharma US IncMyrbetriq | $385 | $10,76512 claims |
| BayerClimara | $184 | $85912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 605 obstetrics & gynecology providers in Connecticut.
Other obstetrics & gynecology in New Britain
- Kyle BakerNew Britain$7K
- Stephanie GarozzoNew Britain$5K
- Lisa RinaldiNew Britain$5K
- Mary MinkinNew Haven$285K
- Alessandro SantinNew Haven$98K
- Frederick RauHartford$89K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
- Mark LeondiresNorwalk$31K
- Alan FineHartford$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.